Related Experiment Videos
Patterns of practice analysis for acute myocardial infarction
R T Tsuyuki1, S Gill, J D Hilton
1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver.
Insights
Proven therapies for acute myocardial infarction (AMI), including acetylsalicylic acid (ASA) and beta-blockers, show underuse in contemporary patients. Thrombolytic therapy use was high, but other essential treatments require further analysis and education.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Background:
- Acute myocardial infarction (AMI) management relies on evidence-based therapies.
- Acetylsalicylic acid (ASA), beta-blockers, and thrombolytic agents are proven efficacious in AMI.
- Assessing contemporary utilization of these therapies is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the utilization of ASA, beta-blockers, and thrombolytic therapy in AMI patients.
- To determine the impact of contraindications and patient-specific factors on treatment use.
- To identify potential gaps in the application of guideline-recommended AMI therapies.
Main Methods:
- Retrospective review of 372 consecutive AMI patients admitted to a tertiary care hospital.
- Calculation of 'gross utilization' and 'adjusted utilization' rates for targeted therapies.
- Analysis accounted for factors like late presentation, diagnostic uncertainty, and contraindications.
Main Results:
- Gross utilization: ASA (71%), beta-blockers (31%), thrombolytic therapy (21%).
- Adjusted early (≤6h) utilization: ASA (66%), beta-blockers (18%), thrombolytic therapy (100%).
- Adjusted late (>6h) utilization: ASA (84%), beta-blockers (57%).
Conclusions:
- Underutilization of ASA and beta-blockers observed, despite proven efficacy in AMI.
- Thrombolytic therapy demonstrated high adjusted utilization.
- Further educational initiatives and practice analysis are recommended to optimize AMI treatment.
Objective:
To assess the level of use of acetylsalicylic acid (ASA), beta-blockers and thrombolytic therapy--proven efficacious therapies in the management of acute myocardial infarction (AMI)--in contemporary patients admitted with AMI, and to assess the role of contraindications and other patient-specific factors in the use or nonuse of these treatments.
Design:
The demographics and treatment course of patients admitted with a diagnosis of AMI were reviewed. Specifically targeted therapies were ASA, beta-blockers and thrombolytic therapy. Rates of use were calculated as 'gross utilization' (overall use) and 'adjusted utilization' (accounting for late presentation to hospital, initially equivocal diagnosis or contraindications).
Setting:
Tertiary care hospital in suburban Vancouver, British Columbia.
Patients:
A total of 372 consecutive patients admitted to Royal Columbian Hospital between September 1, 1990 and September 1, 1991.
Interventions:
None.
Main Results:
Gross utilization of ASA, beta-blockers and thrombolytic therapy was 71, 31 and 21%, respectively. The adjusted utilization rates for early (6 h or less) treatment with ASA was 66%; with early beta-blockers, it was 18% and was 100% for thrombolytic therapy. Adjusted late (more than 6 h, to hospital discharge) use of ASA and beta-blockers was 84 and 57%, respectively.
Conclusions:
With the exception of thrombolytic therapy, proven efficacious medical therapies for AMI appear underused at the study hospital. Ongoing educational efforts and continuing patterns of practice analyses are needed.